Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Researchers are working on patches containing tiny needles that deliver medications through the skin.
Recently, ViiV Healthcare applied for approval of the first long-acting injectable HIV regimen.
A roundup of POZ’s reporting on studies presented at the Mexico City conference about HIV treatment, vaccines, PrEP and other concerns.
The experimental long-acting injectable regimen of cabotegravir and rilpivirine stands poised for approval.
Given every four weeks, the combo injection of cabotegravir and Edurant (rilpivirine) will likely face an FDA decision by early 2020.
An early trial of Gilead’s HIV capsid inhibitor supports three-month dosing.
The trial will investigate whether injections of long-acting cabotegravir and rilpivirine yield a superior rate of viral suppression.
Dosed every four weeks, the injection, which requires a clinic visit, includes long-acting rilpivirine and cabotegravir.
A series of antibody infusions suppressed HIV for up to four months without prompting the virus to develop resistance.
The Conference on Retroviruses and Opportunistic Infections in Seattle saw many important studies that are advancing the fight against HIV.
Participants in a study were started on daily oral drugs and then half were switched over to long-acting meds.
The antiretroviral GS-6207 is injected under the skin and would need to be combined with other meds to fully suppress HIV.
Given every four weeks, combo injections of cabotegravir and rilpivirine will likely face an FDA decision by early 2020.
Researchers have devised a means of injecting an antiretroviral under the skin that hardens into a dissolvable and removable implant.
Periodic infusions of long-acting HIV antibodies may eventually become a new way of treating the virus.
Promising findings from a study of a two-drug injectable treatment given every four weeks.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.